Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096616 · ClinicalTrials.gov registry record · Phase 2
Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 113
- Enrollment target
NCT00096616 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 113 participants.
The verdict
NCT00096616, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 113 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.
Interventions
- DRUG Albuterol HFA MDI
- DRUG Combivent® CFC MDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2004-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00096616
The ClinicalTrials.gov registry entry for NCT00096616 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Albuterol HFA MDI is the first listed.
NCT00096616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00096616 about?
NCT00096616 is a clinical study titled "Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma". The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.
What is the current status of trial NCT00096616?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 113 participants. The study started on 2004-11.
What interventions are being tested in trial NCT00096616?
The interventions under investigation include: Albuterol HFA MDI (DRUG), Combivent® CFC MDI (DRUG).
Who is sponsoring clinical trial NCT00096616?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.